Results 181 to 190 of about 72,745 (302)
Advanced clear cell renal cell carcinoma metastasis is driven by a FOXC2+ tumor subpopulation. These cells execute vasculogenic mimicry for dissemination and secrete LAMA4. LAMA4 engages macrophage ITGA6, activating the STAT6/GATA3 axis to polarize macrophages into a pro‐metastatic, immunosuppressive phenotype.
Jiaxi Yao +11 more
wiley +1 more source
The Real World Impact of Immunoglobulin Replacement Therapy on Severe Bacterial Infection for Patients With Hypogammaglobulinemia Secondary to Hematologic Malignancies: A Japanese Claims Database Study. [PDF]
Mihara K +5 more
europepmc +1 more source
Seasonal Influenza Vaccine: Uptake, Attitude, and Knowledge Among Patients Receiving Immunoglobulin Replacement Therapy. [PDF]
Cox F +4 more
europepmc +1 more source
An AMP (P 3‐3R‐8I) based on natural peptides, which can target bacterial cell membranes, was precisely constructed via amino acid mutation. P 3‐3R‐8I exhibits antibacterial capability which could be attributed to the ability of P 3‐3R‐8I to quickly penetrate bacterial cell membranes and then to bind to bacterial DNA.
Jiaqi Huang +11 more
wiley +1 more source
Evaluation of immunological abnormalities in patients with rare syndromes
Yahya Gul +7 more
doaj +1 more source
Effectiveness, Safety, and Treatment Satisfaction of 20% Subcutaneous Immunoglobulin Replacement Therapy in Pediatric Patients with Primary and Secondary Immunodeficiencies. [PDF]
Sefer AP, Kaya MS.
europepmc +1 more source
Subcutaneous immunoglobulin replacement therapy in a patient with 18q deletion syndrome, primary immune deficiency, and type 1 diabetes. [PDF]
Hogendorf A +6 more
europepmc +1 more source
A multifunctional mPDZM nanoplatform is developed in this study. mPDZM integrates chemotherapy‐induced senescence, selective senolysis, and STING‐mediated immune activation. mPDZM effectively clears senescent tumor cells, remodels the tumor immune microenvironment, and enhances antitumor T‐cell responses.
Shiji Fang +17 more
wiley +1 more source

